A starting point for your conversation
This guide relates to effervescent co-codamol, which contains codeine and paracetamol. Tell the clinician the exact product you have used because formulations can have different ingredients.
This is information about preparing for care. It does not establish whether a medicine is suitable for you or replace advice from your clinician.
What to discuss
Include anything that has changed since a previous assessment. It is fine to say when you do not know an answer.
- Your pain history and the exact formulation previously prescribed
- Other pain medicines, including any containing paracetamol
- Dietary sodium restrictions, health conditions and side effects
Your GP or usual prescriber’s details and your preferences about sharing care information form part of the assessment.
What to have ready
Your current medicines and allergies
Include prescribed medicines, anything bought elsewhere and any reactions you have had.
What you have tried already
Have the treatment names and details of how they worked, including any side effects.
Your GP or usual prescriber’s details
The assessment asks who usually looks after your health and about contact with them.
Previous prescriptions or medical records
These may be needed to verify your treatment history. The clinical team will explain what evidence is required.
What a review can lead to
A clinician may need further information, an examination, records or test results. The outcome may be advice, non-medicine options, a different treatment, a prescription where appropriate, or referral for other care.
Ask about expected benefits, possible side effects, interactions, alternatives and when treatment should be reviewed. An assessment or a previous prescription does not guarantee further prescribing.
Further reading
These primary sources provide additional information. Product information may relate to a specific brand or formulation; always check the leaflet supplied with your own medicine.
- Co-codamol 30/500 effervescent, Zentiva: SmPC
- Co-codamol 30/500 effervescent, Cipla: SmPC
- MHRA: Opioid dependence and addiction
Clinical sign-off is pending. This preview is not a prescribing or dosing guide.